# Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery

> **NCT00950274** · PHASE3 · TERMINATED · sponsor: **Miltenyi Biotec B.V. & Co. KG** · enrollment: 81 (actual)

## Conditions studied

- Myocardial Ischemia
- Coronary Artery Disease

## Interventions

- **DRUG:** CD133+ autologous bone marrow stem cell
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00950274
- **Lead sponsor:** Miltenyi Biotec B.V. & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2016-03
- **Final completion:** 2017-09
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** Recruitment stopped due to slow recruitment
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950274, "Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00950274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*